Photodynamic therapy treatment for eye disease
View Patent ↗This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.
1. A method of treating neovascular disease of the eye, comprising:
administering a conjugate to target neovascular tissue of the eye comprising:
a photosensitizing compound selected from the group consisting of chlorines, bacteriochlorophylls, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, porfimer sodium, delta-aminolevulinic acid protoporphyrin, indocyanine green, benzoporphyrin, methylene blue, toluidine blue, texaphyrins, pyropheophorbide compounds, and verteporfin; and
a targeting moiety that selectively binds to abnormal endothelium, wherein the targeting moiety consists of an antibody or an antibody fragment thereof that binds to a VEGF receptor;
allowing sufficient time for the conjugate to clear from non-targeted tissue of the eye; and
illuminating the eye with a light having a wave length or waveband absorbed by the targeted photosensitizing compound to activate the photosensitizing compound, and
wherein the light has a combination of an intensity of light of less than 500 mW/cm 2 and a duration of illumination of about 4 minutes to produce a total fluence of light irradiation from between about 30 J/cm 2 to about 25,000 J/cm 2 which destroys the targeted neovascular tissue while the non-targeted tissue remains undamaged.
2. The method of claim 1 , wherein the sufficient time for the conjugate to clear from the non-targeted tissue is about 24 hours or less.
3. The method of treating neovascular disease of the eye of claim 1 , wherein the method is performed one time or multiple times in the eye.
4. The method of claim 1 , wherein the light is non-coherent light.
5. The method of claim 1 , wherein the light is coherent light.
6. The method of claim 1 , wherein the neovascular tissue is present in retina, choroids or both.
7. The method of claim 1 , wherein the total fluence of light irradiation from between about 30 J/cm 2 to about 10,000 j/cm 2 .
8. The method of claim 1 , wherein the total fluence of light irradiation from between about 30 J/cm 2 to about 900 J/cm 2 .
9. The method of claim 1 , wherein the eye is illuminated with a light having a wave length or waveband that matches the excitation wave length or waveband of the targeted photosensitizing compound to activate the photosensitizing compound.
10. The method of claim 1 , wherein the neovascular disease is diabetic retinopathy.
11. The method of claim 1 , wherein the neovascular disease is macular degeneration.
12. A method of treating neovascular disease of the eye, comprising:
administering a conjugate to target neovascular tissue of the eye comprising:
a photosensitizing compound selected from the group consisting of chlorines, bacteriochlorophylls, phthalocyanines, porphyrins, purpurins, merocyanines, psoralens, porfimer sodium, delta-aminolevulinic acid protoporphyrin, indocyanine green, benzoporphyrin, methylene blue, toluidine blue, texaphyrins, pyropheophorbide compounds, and verteporfin; and
a targeting moiety that selectively binds to abnormal endothelium, wherein the targeting moiety consists of an antibody or an antibody fragment thereof that binds to a VEGF receptor;
allowing sufficient time for the conjugate to clear from non-targeted tissue of the eye; and
illuminating the eye with a light having a wave length or waveband absorbed by the targeted photosensitizing compound to activate the photosensitizing compound, and
wherein the light has a combination of an intensity of light of less than 500 mW/cm 2 and a duration of illumination of about 4 minutes to about 10 minutes to produce a total fluence of light irradiation from between about 30 J/cm 2 to about 10,000 J/cm 2 which destroys the targeted neovascular tissue while the non-targeted tissue remains undamaged.
13. The method of claim 12 , wherein the total fluence of light irradiation from between about 30 J/cm 2 to about 900 J/cm 2 .
14. The method of claim 12 , wherein the eye is illuminated with a light having a wave length or waveband that matches the excitation wave length or waveband of the targeted photosensitizing compound to activate the photosensitizing compound.
15. The method of claim 12 , wherein the targeted neovascular tissue is present in retina, choroid or both.
16. The method of claim 12 , wherein the neovascular disease is diabetic retinopathy.
17. The method of claim 12 , wherein the neovascular disease is macular degeneration.